Graves Disease Clinical Trial
Official title:
Validating Immunological Markers in Blood and Cerebrospinal Fluid Associated With Mental Fatigue in Graves' Disease and Their Association With Functional Changes in Neuronal Activation
Mental fatigue occurs in many diseases and the reasons are mostly unknown. The investigators hypothesize that remaining mental fatigue after restored euthyroidism in Graves' disease is an autoimmune complication. This is a confirmatory study of the biomarkers from ImmunoGraves WP1 in which immunological markers with possible association with mental fatigue in Graves' disease are explored. In ImmunoGraves WP2, 310 patients with Graves' disease are assessed for symptoms of mental fatigue, quality of life, anxiety and depression, self-evaluated stress, coping strategies, personality traits, eye symptoms and background variables. Participants are examined in hyperthyroidism at inclusion, within three weeks from diagnosis, and in euthyroidism after 15 months. Serum and cerebrospinal fluid (in a subsample of participants) is collected at both visits and will be evaluated for the immunological markers identified in WP1 as well as for thyroid hormones, thyroid autoantibodies and biomarkers indicating organic and structural nerve damage. Significant predictors for mental fatigue will be identified by logistic regression. To assess functional changes in the brain, magnetoencephalography will be performed in a subset of patients and in healthy controls at inclusion and after 15 to 18 months. Combined with magneto resonance imaging (MRI), magnetoencephalography gives information on neuronal activation during attention testing.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
| Completed |
NCT02973802 -
ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
|
Phase 1 | |
| Completed |
NCT02491567 -
DNA Methylation and Autoimmune Thyroid Diseases
|
||
| Terminated |
NCT01320813 -
Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy
|
N/A | |
| Completed |
NCT00432146 -
Effect of Lugol's Solution in the Patients With Graves' Disease
|
N/A | |
| Not yet recruiting |
NCT06327828 -
Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care
|
N/A | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04135573 -
The Relationship Between NK Cell and Graves' Disease
|
||
| Recruiting |
NCT06134219 -
Course for Brain Fatigue After Graves' Disease Controlled Study
|
N/A | |
| Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
| Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
| Completed |
NCT03009357 -
Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
|
||
| Recruiting |
NCT05510609 -
Three-dimensional Ultrasonography Thyroid Volume Measurement.
|
N/A | |
| Not yet recruiting |
NCT06426758 -
Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
|
||
| Recruiting |
NCT05907668 -
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
|
Phase 2 | |
| Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
| Recruiting |
NCT03303053 -
Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism
|
Phase 3 | |
| Recruiting |
NCT05461820 -
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
|
Phase 4 | |
| Recruiting |
NCT06309316 -
The Impact of Person Centred Care (PCC) in Grave's Disease
|
N/A |